Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker

Masayuki Tanemoto, Takaaki Abe, Noriyuki Obara, Michiaki Abe, Fumitoshi Satoh, Sadayoshi Ito

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Three patients who suffered from congestive heart failure caused by severe hypertension were treated with a combination therapy consisting of angiotensin converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB). Before initiation of treatment, all three patients showed elevations of serum creatinine concentration (sCr), plasma renin activity (PRA), and plasma aldosterone concentration (PAC), which indicated insufficient blood supply to the kidney during exacerbation of hypertension. All three cases successfully recovered from hypertensive heart failure with the combination therapy. sCr gradually decreased during continuation of the therapy, although one patient showed an increase in sCr at an early stage of the combination therapy. Blockade of the renin-angiotensin-aldosterone system (RAAS) by the combination of ACEI and ARB was well tolerated in patients with severe hypertension with renal damage and showed a beneficial effect in protecting against further renal damage. This result suggests that combination therapy with ACEI and ARB should be considered as a candidate treatment in cases of severe hypertension.

Original languageEnglish
Pages (from-to)863-868
Number of pages6
JournalHypertension Research
Volume26
Issue number10
DOIs
Publication statusPublished - 2003 Oct

Keywords

  • Angiotensin II
  • Angiotensin converting enzyme inhibitor
  • Malignant hypertension
  • Receptor blocker
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker'. Together they form a unique fingerprint.

Cite this